VERACYTE, INC. (VCYT)
About VERACYTE, INC.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $517.1M
- Net income
- $66.4M
- Total assets
- $1.4B
- Market cap
- $4.5B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.5B
- Shares outstanding
- 93.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 30, 2013
Veracyte, Inc. (VCYT) Stock Price
- Profitable — net income of $66.4M in FY2025.
- Trading 20% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review VERACYTE, INC..
Write a review
News about VERACYTE, INC.
News & sentiment via Polygon.io
Veracyte, Inc.: frequently asked questions
Is Veracyte, Inc. an American company?
Veracyte, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Veracyte, Inc. headquartered?
Veracyte, Inc. is headquartered in South San Francisco, California, United States.
Is Veracyte, Inc. publicly traded?
Yes — Veracyte, Inc. is a publicly traded company. Its stock trades under the ticker symbol VCYT on the NASDAQ.
What does Veracyte, Inc. do?
Veracyte, Inc. is an American Medical Devices company in the Health & Beauty sector.
